Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial

AIMS: In the TRITON-TIMI 38 trial, greater platelet inhibition with prasugrel reduced the first occurrence of the primary endpoint (cardiovascular death, MI, or stroke) compared with clopidogrel in patients with an acute coronary syndrome (ACS) undergoing planned percutaneous coronary intervention....

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Murphy, Sabina A., Antman, Elliott M., Wiviott, Stephen D., Weerakkody, Govinda, Morocutti, Giorgio, Huber, Kurt, Lopez-Sendon, Jose, McCabe, Carolyn H., Braunwald, Eugene
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2008
Onderwerpen:
Clinical Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2567025/
https://ncbi.nlm.nih.gov/pubmed/18682445
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehn362
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items